Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery

This study has been terminated.
(recruitment lower than estimated)
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Pedro Cahn, The Huesped Foundation
ClinicalTrials.gov Identifier:
First received: November 21, 2007
Last updated: June 5, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2010
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)